Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...
Dexcom Inc. revealed data from several studies showing significant benefits of its continuous glucose monitoring technology ...
As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...
Zacks.com on MSN2h
TNDM Stock Likely to Gain From Innovation Amid CompetitionTandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...
Zacks.com on MSN2h
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EUTandem Diabetes Care, Inc.’s TNDM flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company’s LLY Lyumjev (insulin ...
Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...
Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...
In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $115.00. The company’s shares closed last Friday at ...
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback